anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a composition comprising a mixed extract of amla and Hibiscus sabdariffa for preventing hair loss or promoting hair growth. According to the present invention, the composition comprising an extract of amla is safe because of having no cytotoxicity, inhibits expressions of hair loss-causing factors, and promotes expression of hair growth factors. In addition, the composition has an outstanding effect of expanding capillary vessels, thereby having excellent effects of ameliorating hair loss or promoting hair growth. Therefore, the composition can be used in a teabag composition or a functional hair product for ameliorating hair loss or promoting hair growth. Furthermore, the mixed extract of amla and Hibiscus sabdariffa has the advantage of giving synergic effects on hair loss prevention or hair growth promotion, compared to a conventional single extract of amla or Hibiscus sabdariffa. In particular, while a single extract of Hibiscus sabdariffa has seldom or very low effects of preventing hair loss or promoting hair growth, a combination thereof with amla can effectively enhance effects of amla for preventing hair loss or promoting hair growth.
Growth differentiation factor 15 (GDF15) is a stress-response cytokine related to a wide variety of metabolic diseases. However, the impact of GDF15-specific genetic variants on the abovementioned conditions is poorly known. The aim of this study was to assess the impact of selected GDF15 single-nucleotide polymorphisms (SNPs) on metabolic disturbances and subclinical atherosclerosis. A cross-sectional study involving 153 participants of a metabolic patient-based cohort was performed. Three selected SNPs (rs888663, rs1054564 and rs1059369) in a locus on chromosome 19 including the GDF15 gene were genotyped by Polymerase Chain Reaction (PCR), and its relationship with the serum GDF15 levels, health status and clinical variables were analyzed. Of the three SNPs analyzed, only rs1054564 showed different distributions between the healthy volunteers and patients suffering lipid alterations and associated disorders. Accordingly, just the rs1054564 variant carriers showed a significant increase in GDF15 serum levels compared to the wild-type carriers. The group of variant carriers showed a higher frequency of individuals with diabetes, compared to the wild-type carrier group, without showing differences in other metabolic conditions. Additionally, the frequency of individuals with atherosclerotic carotid plaque was higher in the rs1054564 variant carriers than in the wild-type carriers. Logistic regression models identified that the presence of the rs1054564 variant carriers increase the likelihood for both diabetes and carotid plaque independently of confounding factors. Overall, the findings of this study identify the rs1054564 variant as a potential indicator for the likelihood of diabetes and subclinical atherosclerosis.
Consists of up to 80 patients with acute mTBI. All acute mTBI subjects will be scanned per the HHI study design at 3 to 5 timepoints relative to their time of injury ( Visit 1 within 72 hours; Visit 2, 7 +/- 4 days; Visit 3, 30 +/- 7 days; Visit 4, 90 +/- 14 days; Visit 5, 180 +/- 30 days from injury). Even though for practicality Visits 1 and 5 are optional, every effort will be made to image as close to the time of acute injury as possible and to complete imaging for all time points.
The invention relates to a Chinese patent medicine for treating chronic gastritis, the gastric ulcer and the duodenal ulcer, and a preparation method thereof. The Chinese patent medicine is composed of Fructus Polygoni Orientalis, Rhizoma Curcumae, Rhizoma Cyperi, Rhizoma Alpiniae Officinarum, cuttlefish bone and an Atropa belladonna extract. Fructus Polygoni Orientalis is used for dyspepsia and swelling pains in the gastral cavity; Rhizoma Curcumae can be used for qi condensation, blood stasis, and swelling pains in the stomach duct, abdomen, chest and hypochondrium; and the above two medicines are monarch medicines, contain a plurality of effective components, and have multiple pharmacological effects comprising antibiosis, antivirus, anti-inflammation and the like, and the compatible use of the two medicines has a beneficial synergistic effect. Rhizoma Cyperi is used for swelling pains in the stomach, abdomen, chest and hypochondrium caused by liver-qi stagnation, and the compatible use of Rhizoma Cyperi and Rhizoma Alpiniae Officinarum can be used for treating stomach cold and pains, and has a substantial helicobacter pylori resistance. The compatible use of Rhizoma Cyperi and cuttlefish bone has acid prevention and gastric mucosa protection effects. The compatible use of Rhizoma Cyperi and Atropa belladonna can effectively relieve pains. The mixed us of all the above medicines in the above formula can tonify spleen yang, warm stomach cold, dissipate qi stagnation, dissolve stasis and relieve pains to realize no pains through stasis elimination, can restore the gastric mucosa, and can effectively treat the digestive ulcer. All the above medicines are processed through a modern pharmaceutical technology to prepare a traditional Chinese medicinal compound preparation, so the traditional Chinese medicinal compound preparation has the advantages of advanced technology, full performance of the medicine efficacies, simultaneous treatment of principal and subordinate symptoms, safe and convenient use, and substantial curative effects and no obvious side effects after the clinic use for many years.
This group will come to visits every three months up to diagnosis or 18 years of age. At the visits blood samples are drawn and disease risk information and information about symptoms is given. An OGTT will be performed at some of the visits. The child will wear an accelerometer and a CGM for one week after each visit.
Sucralfate is only minimally absorbed from the gastrointestinal tract. The small amounts of the sulfated disaccharide that are absorbed are excreted primarily in the urine.

Although the mechanism of sucralfate’s ability to accelerate healing of duodenal ulcers remains to be fully defined, it is known that it exerts its effect through a local, rather than systemic, action. The following observations also appear pertinent:

1\. Studies in human subjects and with animal models of ulcer disease have shown that sucralfate forms an ulcer-adherent complex with proteinaceous exudate at the ulcer site.

2\. In vitro, a sucralfate-albumin film provides a barrier to diffusion of hydrogen ions.

3\. In human subjects, sucralfate given in doses recommended for ulcer therapy inhibits pepsin activity in gastric juice by 32%.

4\. In vitro, sucralfate adsorbs bile salts.

These observations suggest that sucralfate’s antiulcer activity is the result of formation of an ulcer-adherent complex that covers the ulcer site and protects it against further attack by acid, pepsin, and bile salts. There are approximately 14 to 16 mEq of acid-neutralizing capacity per 1 g dose of sucralfate.
Participants attended 4 2-hr nutrition education sessions. Each session provided information and encouragement on setting and attaining measurable goals for healthy eating and on the benefits of thinking positively about dealing adaptively with problems in life and living a healthy lifestyle.
Gastric Cancer (GC) is a lethal malignancy, with urgent need for the discovery of novel biomarkers for its early detection. I previously showed that Transposable Elements (TEs) become activated in early GC (EGC), suggesting a role in gene expression. Here, I follow-up on that evidence using single-cell data from gastritis to EGC, and show that TEs are expressed and follow the disease progression, with 2,430 of them being cell populations markers. Pseudotemporal trajectory modeling revealed 111 TEs associated with the origination of cancer cells. Analysis of spatial data from GC also confirms TE expression, with 204 TEs being spatially enriched in the tumor regions and the tumor microenvironment, hinting at a role of TEs in tumorigenesis. Finally, a network of TE-mediated gene regulation was modeled, indicating that ~ 2,000 genes could be modulated by TEs, with ~ 500 of them already implicated in cancer. These results suggest that TEs might play a functional role in GC progression, and highlights them as potential biomarker for its early detection.
A consumer product comprising a delivery particle having a core and a wall encapsulating the core. The core comprises a benefit agent and a partitioning modifier, e.g. a fragrance oil and isopropyl myristate. The wall is formed by a radical polymerisation reaction between a) a water-soluble polysaccharide comprising at least one amine group, e.g. chitosan; b) at least one of a multifunctional (meth)acrylate monomer or oligomer, e.g. a hexafunctional aromatic urethane acrylate oligomer; c) at least one water-soluble thermal free radical initiator; d) at least one oil soluble thermal free radical initiator. At least one of the water-soluble initiators is a persulfate, e.g. potassium persulfate, ammonium persulfate or sodium persulfate.
Patients newly diagnosed with breast cancer face a series of complex decisions regarding locoregional and systemic treatment. Currently many of these decisions do not meet the definition of a high quality decision, defined as one that is both informed (i.e., based on an accurate understanding of the treatment risks and benefits) and preference-concordant (i.e., consistent with the patients' underlying preferences). Moreover, the introduction of evaluative tests has made these decisions more complicated for many patients. There is a need to improve the quality of locoregional and systemic treatment decisions for breast cancer patients, and to help patients understand the role of evaluative tests in this decision process. Ensuring patients can deliberate effectively about these decisions, assert their views and communicate with their clinicians is likely to improve their overall decision preparedness and satisfaction. This study will focus on the third pillar of individualized care by evaluating the impact of an innovative decision tool on locoregional and systemic therapy decision making for newly diagnosed breast cancer patients. The innovative online decision tool has been developed and tested over the past two years by the CanSORT team (R21 CA129859). Pilot data suggests that this tool has a positive impact on patient knowledge and decision outcomes. The goal of this study is to evaluate the impact of this tool, after it is enhanced in collaboration with our Communication and Dissemination Core, on the quality of decision making for locoregional and systemic breast cancer treatment decision making.
The invention relates to a composition for injection for treating orthopedic diseases. The composition is prepared by taking pig trotter bones and muskmelon seeds respectively subjected to extraction as raw materials. The composition mainly contains polypeptide bone metabolic factors, a muskmelon seed extract, various free amino acids, inorganic salts and trace elements, wherein bioactive peptides containing various bone metabolisms have a function of treating various orthopedic diseases. An especially noteworthy thing is that post-shin bones of pigs are preferably selected as the raw material of the composition disclosed by the invention, the ultraviolet absorption peak of polypeptide compositions in extracting liquid of the post-shin bones of pigs is about 258nm, and the ultraviolet absorption peak of polypeptide compositions in common pig trotter bones is about 240-250nm. Experiments show that by taking post-shin bones of pigs as pharmaceutical raw materials, the composition can play a good therapeutic role. In the process of preparation, by respectively carrying out monitoring on extracting liquid of muskmelon seeds and extracting liquid of post-shin bones of pigs at the ultraviolet absorption peak of 258nm, and preposing a pharmaceutical standard monitoring link, the pharmaceutical standard is improved, and the effectiveness and safety of pharmaceuticals are ensured effectively.
The invention belongs to the technical field of medicines, and relates to application of kynurenic acid in preparation of medicines for relieving and/or treating bulimia nervosa. According to the invention, an animal model of BN pathogenesis is established on mice, and through sequencing of a mouse fecal microorganism metabolome, the KYNA is found to be obviously reduced in the intestinal tract of the BN mice. The WB detection shows that the protein expression level of KYNA synthetase KAT I/II/III in the intestinal tract of the BN mouse is also obviously reduced, which indicates that the synthesis of KYNA in the intestinal tract is blocked. Through the targeted metabolic substance spectrum detection of the excrement of the BN patient, the KYNA in the intestinal tract of the BN patient is found to show the descending change compared with the normal test. Finally, BN mice were subjected to oral KYNA treatment for 11 days, which treatment was found to improve the bulimia symptoms in BN mice. Therefore, the purpose of treating BN from the root mechanism can be achieved by orally supplementing KYNA to recover the intestinal metabolite level, and a new method is provided for clinically treating BN.
The relationship between stroke volume, which is extruded from the left ventricle gives a measure for the restrictive left ventricular function. Any patient with known cardiovascular disease should undergo assessment of left ventricular function by measuring the ejection fraction. Several studies have shown that when the ejection fraction (LVEF), which measures the heart's ability to eject blood to the aorta does not exceed 40% (natural price \^ 50%) increased dramatically in the post-infarction mortality. The ejection fraction as a reliable predictor, can be measured by ultrasonography. The reduced ejection fraction is associated with an increased risk of life-threatening arrhythmias, heart failure and death. The low ejection fraction, especially after myocardial infarction is a strong indication for beta-blockers, as many studies indicate that administration of these drugs substantially reduces cardiovascular mortality.
First, an individual information form will be filled in for the control group patients who meet the sampling criteria. 0-2-4-8-12-24 after the patients come to the service after the surgery. Routine pain assessment will be done at In addition, the type, route, effect and amount of analgesic done in this process will also be recorded. Response evaluation will follow.
Exercise protocol consisting of: eccentric and concentric strengthening of quadriceps (three squat series of 20 repetitions), hamstrings (three series of 20 seconds performing the bridge exercise), gluteus medius (three series of 20 seconds performing the clam exercise), gastrocnemius and soleus (three series of stretching exercises for 1 minute each). These exercises will be performed along 20 minutes approximately with a minute of rest between each exercise series, never exceeding 3mm in VAS. Participants have to assist to a local facility center to be supervised at doing the exercises daily (from Monday two Friday) along three weeks.
Thereto a method and a system for planning radiation therapy are provided, as well as an arrangement for radiation therapy planning and a computer program product for carrying out the method. For planning the radiation therapy, the following steps are performed. Patient data of a subject to be treated is received as well as image data of the subject to be treated. The image data comprises anatomical image data of one or more organs at risk associated with the functioning of the immune system. Next, the patient 122 data and the image data are processed to obtain a risk score for the one or more organs at risk associated with the functioning of the immune system. The risk score is indicative of the risk of hematologic toxicity in the subject to be treated in response to the radiation therapy. Then the radiation therapy treatment is planned using the obtained risk score.
PROBLEM TO BE SOLVED: To provide the subject composition excellent in dandruff proof action and free from discoloration in long time storage containing selenium disulfide and a zinc salt of an inorganic acid or an organic carboxylic acid as a stabilizer in an aqueous medium. SOLUTION: This composition contains (A) selenium disulfide in a mixture with (B) a zinc salt of an inorganic acid or an organic carboxylic acid (preferably zinc chloride, zinc lactate or zinc citrate) in an aqueous medium. Preferably (A) is a powder having particle size <2.5mm. The preferable amount of ingredient (A) is 0.25-2wt.% and ingredient (B) is 0.1-3wt.% based on the total weight of the composition. The weight ratio of ingredient (B) to ingredient (A) is preferably 0.2-2. The composition is preferably used as shampoo and in this case 0.05-30wt.% of a surfactant is preferably formulated. Water or a mixture of water and ethanol is preferred as an aqueous medium.
BACKGROUND: Endoscopic resection (ER) is a minimally invasive treatment for esophageal cancer that sometimes causes complications. To understand the real-world incidence and risk factors for these complications, a nationwide survey was conducted across Japan.
METHODS: This retrospective multicenter study included patients who underwent ER for esophageal cancer from April 2017 to March 2018 (2017 complication analysis) and April 2021 to March 2022 (2021 complication analysis). The study assessed the complication rates and conducted risk factor analyses for endoscopic submucosal dissection (ESD) using data for these patients, with exclusions based on specific criteria to ensure data accuracy.
RESULTS: In the 2021 complication analysis, there were two mortalities highly likely attributable (0.03%) to ER and one mortality possibly attributable (0.01%) to ER. Intraoperative perforation, delayed bleeding, and pneumonia occurred in 137 cases (1.8%), 44 cases (0.6%), and 130 cases (1.7%), respectively. In the multivariate analysis for complications after ESD, low ER volume of the facility was an independent risk factor for perforation, while lesion location in the cervical or upper thoracic esophagus was an independent factor for reduced risk of perforation. Age ≥ 80 years was a risk factor for pneumonia, while use of traction techniques was a factor for reduced risk of pneumonia. Lesions located in the middle thoracic esophagus had a lower risk of stricture, and the risk of stricture increased as the circumferential extent of the lesion increased.
CONCLUSIONS: This large-scale study provided detailed insights into the complications associated with esophageal ER and identified significant risk factors.
The role of triage in the Emergency Department (ED) is to assign high priority to patients who need urgent care while identifying patients that may be able to wait safely. The Canadian Triage and Acuity Scale (CTAS) is a triage tool constructed from a consensus of experts that is universally used in Canada. Until now, there has been no evaluation of the validity of the tool for children in a clinical context. Also, its inter-rater reproducibility has not been evaluated. The expected implementation of a revised version of the Canadian triage tool in 2008 would be an ideal moment to evaluate its validity and reproducibility. Specific objective: 1. To evaluate the validity of the CTAS for children visiting a pediatric ED and 2. To measure the inter-rater agreement for nurses using the CTAS in these settings.
A system and method for conditionally diagnosing, assessing and tracking the symptoms of patients having mental or physical disorders involves providing an interview instrument having diagnostic and assessment information for a selected disorder. A clinician conducts a first interview of a patient to identify and assess the patient's symptoms. The clinician records the symptoms and assessment on the interview instrument. Alternatively, the patient records symptoms on the interview instrument and the clinician then conducts a first interview. The clinician develops a diagnosis and treatment plan and records them on the instrument. The clinician conducts one or more subsequent interviews of the patient for identifying and assessing the patient's symptoms and records any changes in the symptoms on the interview instrument for documenting the effects of the treatment plan. The interview instrument includes a joint use portion having a list of symptoms and assessment criteria and spaces for recording the patient's symptoms and an assessment, a diagnostic portion having predetermined, recognized diagnostic criteria for use by the clinician, a patient-use portion having educational information for use by the patient and a follow-up portion for tracking the effects of a treatment plan across multiple subsequent visits.
PROBLEM TO BE SOLVED: To obtain the subject inhibitor having strong α-glucosidase inhibitory activity, being readily taken by making the inhibitor include a plant belonging to the family Brassicaceae as an active ingredient. SOLUTION: This inhibitor contains a plant belonging to the family Brassicaceae as an active ingredient. For example, Japanese radish, Roripa nasturtium-aquaticum, horse-radish, cabbage, turnip, etc., may be cited as the plant belonging to the family Brassicaceae. Though the plant belonging to the family Brassicaceae is used in an ordinary state, further dried and powdered or ground in water into a slurried state and the slurried plant may show glucosidase inhibitory activity, an extract obtained by using water and/or an alcohol preferably provides stronger α-glucosidase inhibitory activity. An extract obtained by using a mixed solution of water and an alcohol is especially preferable. Ethanol is preferable as the alcohol. The weight ratio of water/the alcohol is preferably 1/100 to 100/1, more preferably 1/50 to 50/1.
The invention discloses a Bt Cry1A antibody and its preparation, and exclusive-use antigen and its application. Its purpose is to supply a Bt Cry1A antibody and its preparation, and exclusive-use antigen and its application in making Bt immunoassay kit. The exclusive-use antigen of the Bt Cry1A antibody is made by combing the carrier protein and polypeptide which has the same amino acid residue sequence as the SEQ ID No:1 in the sequence table. The Bt Cry1A is gained through separating and purifying blood serum from exclusive-use antigen immune animal. The antibody has the following advantages that it has higher specificity; the detection sensitivity can reach 52.7ng per mL; it can be used to do qualitative and quantitative analysis in the toxoprotein of the transform Bt plant, such as cotton, corn, paddy, tobacco, and so on; its preparation method is simple, and has the industrialization production feasibility. The invention will play an important role in the biological detect of the transforming Bt plant, and has far reaching market prospect.